RXi Pharmaceuticals (RXII) Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors
4/22/2013 6:32:10 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that H. Paul Dorman and Curtis Lockshin, Ph.D. have been appointed to the Company’s Board of Directors. Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi’s growth and development initiatives.
Help employers find you! Check out all the jobs and post your resume.
comments powered by